GlassScriptPhysician profile
John F Vu
NPI 1841450780
$3,559.81
in general payments reported to CMS, 2019-2025
14 companies · $339 in 2025
The $339 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,053 · 2020: $188 · 2021: $191 · 2022: $276 · 2023: $373 · 2024: $1,140 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,163 · Travel and Lodging: $640 · Education: $48.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,162.81 |
| Travel and Lodging | $640.31 |
| Education | $48.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,662.97 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept, Clinical Trial Product |
| Abbott Laboratories | $929.24 | 2019-2024 | Eterna |
| Mml US, INC. | $216.56 | 2025 | Reactiv8 |
| Nevro Corp. | $177.38 | 2019-2024 | Senza |
| Biodelivery Sciences International, INC. | $162.89 | 2019-2021 | |
| Painteq LLC | $145.67 | 2023-2024 | Painteq |
| Medtronic, INC. | $103.52 | 2021-2025 | Intellis Adaptivestim |
| Medtronic USA, INC. | $33.46 | 2019-2020 | |
| Saluda Medical Americas, INC. | $29.19 | 2024 | Evoke |
| Relievant Medsystems, INC. | $27.41 | 2023 | Intracept |
| Allergan, INC. | $23.90 | 2020-2021 | |
| Axonics, INC. | $21.06 | 2020 | |
| Biogen, INC. | $16.22 | 2021 | |
| Nalu Medical, INC. | $10.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.